Global General Anesthesia Drugs Market

General Anesthesia Drugs Market Size, Share, Growth Analysis, By Drug Type (Propofol, Sevoflurane), By Route of Administration (Intravenous, Inhaled), By End-Use (Hospitals, Ambulatory Surgical Centers), By Application, By Region - Industry Forecast 2025-2032

Report ID: SQSG30B2035 | Region: Global | Published Date: February, 2024
Pages: 260 | Tables: 118 | Figures: 77

General Anesthesia Drugs Market Competitive Landscape

The global market for general anaesthesia drugs is extremely fragmented, with multiple rivals in the development of general anaesthetic drugs. These firms are employing techniques such as mergers and acquisitions, partnerships and collaborations, and new product releases to match consumer demand and increase their client base. Furthermore, firms operating in the market are obtaining favourable findings for the potential effect of chemicals such as general anaesthesia, which might raise market growth even further. For instance, In June 2021, PAION AG, a speciality pharmaceutical firm, received favourable findings in the European Phase III trial for Remimazolam. It is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic that is licenced for procedural sedation in the United States, Europe, and China, as well as general anaesthesia in South Korea and Japan. By the end of 2021, PAION AG intends to file an extension modification to the Marketing Authorization for remimazolam as general anaesthesia. As a result, the company's actions will broaden the market perspective in numerous areas, adding to market growth.

General Anesthesia Drugs Market Top Player's Company Profiles

  • AstraZeneca (UK) 
  • Baxter International Inc. (USA) 
  • Fresenius SE & Co. KGaA (Germany) 
  • AbbVie Inc. (USA) 
  • B. Braun Melsungen AG (Germany) 
  • Hikma Pharmaceuticals PLC (UK) 
  • Teva Pharmaceutical Industries Ltd. (Israel) 
  • Pfizer Inc. (USA) 
  • Novartis AG (Switzerland) 
  • Mylan N.V. (USA) 
  • Piramal Enterprises Limited (India) 
  • Eisai Co., Ltd. (Japan) 
  • F. Hoffmann-La Roche Ltd. (Switzerland) 
  • GlaxoSmithKline plc (UK) 
  • Johnson & Johnson (USA) 
  • Merck & Co., Inc. (USA) 
  • Sanofi S.A. (France) 
  • Sun Pharmaceutical Industries Ltd. (India) 
  • Takeda Pharmaceutical Company Limited (Japan) 
  • Abbott Laboratories (USA) 

General Anesthesia Drugs Market Recent Development

  • In February 2022, Sedana Medical AB has launched Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) will be approved by the European DCP In addition, in July 2021. the product has been granted national approval in 14 nations. Additional marketing clearance applications were submitted in the same year, and the business expects to gain national approvals in Italy, Poland, Switzerland, and the United Kingdom in 2022.
  • In January 2022, Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratoires Théa SAS (Théa). Théa will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic intended for ocular surface anaesthetic during ophthalmologic operations, as a result of the strategic move.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global General Anesthesia Drugs Market size was valued at USD 4.95 billion in 2022 and is poised to grow from USD 5.13 billion in 2023 to USD 6.86 billion by 2031, growing at a CAGR of 3.7% during the forecast period (2024-2031).

The global market for general anaesthesia drugs is extremely fragmented, with multiple rivals in the development of general anaesthetic drugs. These firms are employing techniques such as mergers and acquisitions, partnerships and collaborations, and new product releases to match consumer demand and increase their client base. Furthermore, firms operating in the market are obtaining favourable findings for the potential effect of chemicals such as general anaesthesia, which might raise market growth even further. For instance, In June 2021, PAION AG, a speciality pharmaceutical firm, received favourable findings in the European Phase III trial for Remimazolam. It is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic that is licenced for procedural sedation in the United States, Europe, and China, as well as general anaesthesia in South Korea and Japan. By the end of 2021, PAION AG intends to file an extension modification to the Marketing Authorization for remimazolam as general anaesthesia. As a result, the company's actions will broaden the market perspective in numerous areas, adding to market growth. 'AstraZeneca (UK) ', 'Baxter International Inc. (USA) ', 'Fresenius SE & Co. KGaA (Germany) ', 'AbbVie Inc. (USA) ', 'B. Braun Melsungen AG (Germany) ', 'Hikma Pharmaceuticals PLC (UK) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Pfizer Inc. (USA) ', 'Novartis AG (Switzerland) ', 'Mylan N.V. (USA) ', 'Piramal Enterprises Limited (India) ', 'Eisai Co., Ltd. (Japan) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'GlaxoSmithKline plc (UK) ', 'Johnson & Johnson (USA) ', 'Merck & Co., Inc. (USA) ', 'Sanofi S.A. (France) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Abbott Laboratories (USA) '

In recent decades, cancer has become much more common in the United States. The National Cancer Institute estimates that there are 16.9 million cancer survivors in the United States. The number of cancer survivors is expected to reach 22.2 million by 2030. The most common cancers are lung and bronchus cancer, breast cancer, prostate cancer, melanoma of the skin, colon and rectum cancer, bladder cancer, non-Hodgkin lymphoma, endometrial cancer, leukemia, kidney and renal pelvic cancer, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order based on estimated new cases in 2020). Prostate, lung, and colorectal cancers will account for 43% of all cancers diagnosed in men by 2020. Breast, lung, and colorectal cancer, on the other hand, accounted for more than half of all new malignancies diagnosed in women in 2020. Because cancer surgery offers the best chance of curing many tumors, particularly if the cancer is contained, the increased prevalence of cancer will result in an increase in the number of procedures. Because general anaesthesia is frequently used for surgical operations to treat cancer, the US general anaesthesia market will grow as the prevalence of cancer rises.

Researchers are heavily focused on anaesthetic drug research and development, which can be contributed to driving the growth of the general anaesthesia market throughout the forecast period. For example, in August 2021, researchers from the University of Michigan and the Washington University School of Medicine in St. Louis conducted experiments to determine which common anaesthetic medications will provide the best clinical outcomes and patient recovery experiences. The study comprised well-known anaesthetic medications such inhaled anaesthetics and intravenous propofol.

North America currently dominates the anaesthetic drugs industry and is anticipated to maintain its dominance over the forecast year. The United States has the world's largest regional market. With the introduction of COVID-19, the United States experienced severe shortages of critical anaesthetic medicines, including midazolam, dexmedetomidine, propofol, and neuromuscular blocking agents. As a result, numerous corporations are increasing their anaesthetic medication manufacturing. For instance, Hikma Pharmaceutical introduced a brand-new medicine, "Propofol Injectable Emulsion," in the United States. Furthermore, this market is being pushed by an increase in the number of operations, an ageing population with an increase in chronic illnesses, and developments in anaesthetic technology.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Local Anesthesia Drugs Market
Buy Now GET FREE SAMPLE
Dental Anesthesia Market
Buy Now GET FREE SAMPLE
Paresthesia Treatment Market
Buy Now GET FREE SAMPLE
Analgesics Market
Buy Now GET FREE SAMPLE
Prescription Drugs Market
Buy Now GET FREE SAMPLE
Generic Drugs Market
Buy Now GET FREE SAMPLE
Benzodiazepine Drugs Market
Buy Now GET FREE SAMPLE
Narcolepsy Drugs Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global General Anesthesia Drugs Market

Report ID: SQSG30B2035

$5,300
BUY NOW GET FREE SAMPLE